steenbjere

Pharvaris announces the company-wide support of hae day :-) 2022. Pharvaris has supported the HAE community by partaking in the hae day :-) Activities Challenge for the 30 days leading up to awareness day. Pharvaris colleagues from across the globe participated in both individual and team activities to promote overall wellbeing and submitted more than [...]

KalVista Pharmaceuticals, Inc.'s proposed name “sebetralstat” has been approved by the World Health Organization’s International Nonproprietary Names (WHO-INN) Expert Committee and the American Medical Association’s United States Adopted Names (AMA-USAN) Council for the drug candidate formerly known as KVD900. Sebetralstat is currently being evaluated in the Phase 3 KONFIDENT study as a potential therapeutic for on-demand [...]

Astria Therapeutics, Inc. reports financial results for the first quarter ended 31 March 2022 and provides corporate update. “We are looking forward to advancing STAR-0215 into the clinic this year with the Phase 1a trial, which we plan to initiate shortly after our anticipated mid-year Investigational New Drug filing. We expect initial results by year-end,” [...]

Pharvaris presents its financial results for the first quarter ended 31 March 2022 and updates recent business highlights. “We met our operational goals for PHVS416 for the on-demand treatment of HAE attacks and have reached our target patient enrollment in the RAPIDe-1 Phase 2 study,” says Berndt Modig, CEO of Pharvaris. “We sincerely thank the [...]

At the Intellia Therapeutics, Inc. operational highlights and financial results for the first quarter ended 31 March 2022, President and CEO John Leonard, M.D., says: “We continue to advance our second in vivo candidate, NTLA-2002, which benefits from the modularity of our platform. We look forward to another important clinical milestone in the second half of [...]

From the BioCryst Pharmaceuticals, Inc. financial results for the first quarter ended 31 March 2022: “We are now over a year into the ORLADEYO launch and are excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers. These trends continued in the first quarter [...]

Héma-Québec has awarded a two-year tender for TAKHZYRO® (lanadelumab injection) as the sole option for prophylaxis subcutaneous treatment for type I/II HAE patients. The two-year term which began 1 April 2022, includes the option for Héma-Québec to extend the tender for an additional two years. “My team and I took part in the clinical trials [...]

TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of HAE in adult and pediatric patients 12 years of age and older. Approved by the U.S. Food and Drug Administration on 8 February 2022, the TAKHZYRO prefilled syringe is ready to use and requires fewer preparation steps than the single-dose [...]

The Phase 3 SHP643-301 study evaluating the safety profile and pharmacokinetics of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events [...]